Citadel Advisors
KLRS

Citadel Advisors’s Kalaris Therapeutics KLRS Stock Holding History

Citadel Advisors’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4
Closed -$42 – 15894
2024
Q4 		$42 Sell
4
-5
-56% -$76 ﹤0.01% 14393
2024
Q3 		$162 Sell
9
-126
-93% -$2.2K ﹤0.01% 14084
2024
Q2 		$2.24K Buy
135
+35
+35% +$618 ﹤0.01% 13717
2024
Q1 		$1.74K Sell
100
-204
-67% -$3.33K ﹤0.01% 14089
2023
Q4 		$4.76K Sell
304
-870
-74% -$34.3K ﹤0.01% 13485
2023
Q3 		$58K Buy
1,174
+639
+119% +$43.5K ﹤0.01% 11579
2023
Q2 		$41.8K Sell
535
-769
-59% -$73.1K ﹤0.01% 12024
2023
Q1 		$118K Buy
1,304
+617
+90% +$78.6K ﹤0.01% 11021
2022
Q4 		$81.1K Sell
687
-304
-31% -$51.6K ﹤0.01% 11516
2022
Q3 		$180K Buy
+991
New +$154K ﹤0.01% 10512

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors's KLRS Position: Q1 2025 in Review

Citadel Advisors sold out of Kalaris Therapeutics (KLRS) in Q1 2025, closing a stake of 6,674 shares — an estimated $64.5K sold.

Citadel Advisors first reported a position in KLRS in Q3 2020 and held it in 11 quarters. The position peaked at $1.06M in Q3 2020. 32 funds tracked by Wall St. Rank hold KLRS as of Q1 2025.

  • Citadel Advisors reported no remaining Kalaris Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Citadel Advisors sold 6,674 Kalaris Therapeutics shares in Q1 2025, an estimated $64.5K.
  • Citadel Advisors first reported a position in Kalaris Therapeutics in Q3 2020 and held it in 11 quarters.
  • Citadel Advisors's Kalaris Therapeutics position peaked at $1.06M in Q3 2020.
  • 32 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2025.

Based on Citadel Advisors's 13F filing for Q1 2025, filed 15 May 2025.